Vaccines sales slump sees GSK's results miss estimates

29 July 2020

GlaxoSmithKline (LSE: GSK) missed analyst estimates for its sales and profit figures in its second quarter 2020 results.

The UK pharma major reported group sales of £7.6 billion ($9.9 billion), a 2% decline on the same period of 2019 and below an analysts’ average estimate of £7.7 billion.

While the company’s Pharmaceuticals unit sales slipped 5% to £4.1 billion and there was a 25% jump in Consumer Healthcare sales to £2.4 million, for the Vaccines business the figure was £1.1 billion, which represents a 29% slump on a year ago.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK